H. Lundbeck A/S
Global Clinical Research – Paediatric Neuro-Psychiatry
Ottiliavej 9
2500 Valby - Denmark
Website

Project leader

Ioana Florea
 
Phone +45 363 013 11
Fax +45 364 382 15
E-Mail  

 

Institute presentation

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 50 years, we have been at the forefront of research within neuroscience. Our key areas of focus are alcohol dependence, Alzheimer's disease, bipolar disorder, depression/anxiety, epilepsy, Huntington's disease, Parkinson's disease, schizophrenia, stroke and symptomatic neurogenic orthostatic hypotension (NOH).

An estimated 700 million people worldwide are living with brain disease and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain disease — we call this Progress in Mind.

Click here to read more.

Our approximately 6,000 employees in 57 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more 100 countries. We have research centers in China, Denmark and the United States and production facilities in China, Denmark, France and Italy. Lundbeck generated revenue of approximately DKK 13.5 billion in 2014 (EUR 1.8 billion; USD 2.4 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com.

 

Quick Links

You can contact us with queries and suggestions using our form.

TACTICS has assembled a strong multidisciplinary team of preclinical and clinical top researchers.

To facilitate the organisation and management, the project is structured in “Work Packages” which together comprise the project.